{"slug":"tb-500","verification":{"valid":true,"entries":63,"head":"5fec39af3770cd4c0e85af9a2bb2855b636fcfb0b17229556f0b029b21bea6e2"},"energy":{"passes":63,"tokens_in":179626,"tokens_out":7312,"tokens_total":186938,"cost_usd":0,"models":{"grok/grok-4.3":25,"grok-4.3":21,"repair":5,"kimi/moonshot-v1-8k":1,"gemini/gemini-2.5-flash":1,"system/audit-repair":9,"owner":1},"head":"5fec39af3770cd4c0e85af9a2bb2855b636fcfb0b17229556f0b029b21bea6e2"},"provenance":[{"ts":"2026-06-29T08:31:03.974Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: TB-500: Thymosin Beta-4\n\nGeneral evidence-graded intro for TB-500: Thymosin Beta-4. Data-first peptide definition article.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"tb-500-thymosin-beta-4\",\n  \"title\": \"TB-500: Thymosin Beta-4\",\n  \"body\": \"## Overview\\nTB-500 is a synthetic peptide fragment corresponding to the active region of thymosin beta-4 (Tβ4).\\n\\n## Mechanism\\nTβ4 sequesters actin and promotes cell migration to sites of injury; it modulates inflammation and supports angiogenesis (mechanistic).\\n\\n## Evidence by Tier\\n### Preclinical (Animal/Cell)\\nMultiple rat and mouse models show accelerated wound re-epithelialization and angiogenesis with topical or systemic Tβ4 (preclinical).\\n\\n### Human Trials\\nPhase 1 intravenous safety studies in healthy volunteers reported good tolerability with no dose-limiting toxicity (human).\\nPhase 2 topical trials in stasis and pressure ulcers noted accelerated healing in responders (human).\\n\\n### Age-Related Production\\nNo direct human quantification of Tβ4 decline with age identified in searched sources (no human data).\\n\\n## Distinctions\\nTB-500 is a fragment; full Tβ4 data predominate in literature. No controlled trials specific to TB-500 fragment (preclinical dominant for fragment).\",\n  \"register\": \"source_ledger\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration.\",\n      \"section\": \"Mechanism\",\n      \"tier\": \"mechanistic\",\n      \"source_ids\": [\"s1\"],\n      \"source_status\": \"sourced\",\n      \"why_material\": \"Core described activity separating repair from suppression.\"\n    },\n    {\n      \"id\": \"c2\",\n      \"text\": \"Topical or systemic Tβ4 accelerates wound healing and re-epithelialization in rat full-thickness wound models.\",\n      \"section\": \"Preclinical\",\n      \"tier\": \"preclinical\",\n      \"source_ids\": [\"s2\"],\n      \"source_status\": \"sourced\",\n      \"why_material\": \"Distinguishes rat data from human.\"\n    },\n    {\n      \"id\": \"c3\",\n      \"text\": \"Intravenous synthetic Tβ4 was well tolerated in Phase 1 single- and multiple-dose studies in healthy volunteers with no dose-limiti","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"f7d4ce982260ae3f3ca664d2d425c795d328e70514469b041f9b77539ce4e4de"},{"ts":"2026-06-29T09:36:04.257Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f7d4ce982260ae3f3ca664d2d425c795d328e70514469b041f9b77539ce4e4de","hash":"767b5ac92a2a5809ff8b4e1f4ebcd16038f51e744a2e16160c626e269e17410a"},{"ts":"2026-06-29T09:36:23.605Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"767b5ac92a2a5809ff8b4e1f4ebcd16038f51e744a2e16160c626e269e17410a","hash":"b381b57ff9b36bc084cb18acb537deb63e52429a31111a08355a6c96ba0ea8c9"},{"ts":"2026-06-29T09:36:52.043Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b381b57ff9b36bc084cb18acb537deb63e52429a31111a08355a6c96ba0ea8c9","hash":"cb8548ba7c96230e4c00f052fbc041bd797ee3ccd739484215dc91ca4eb75d69"},{"ts":"2026-06-29T09:37:13.143Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"cb8548ba7c96230e4c00f052fbc041bd797ee3ccd739484215dc91ca4eb75d69","hash":"07939679402db61c75bce3fb9b70909eca9fa10599bc95c721c99a4e06d4e05e"},{"ts":"2026-06-29T10:20:41.395Z","model":"repair","action":"repair","prompt":"","input":"tb-500","response":"{\"materialized\":24,\"before\":[\"5 claims missing posted_by\",\"24 orphan sources (no claim link)\",\"missing constitution slots: who_claims_what, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"07939679402db61c75bce3fb9b70909eca9fa10599bc95c721c99a4e06d4e05e","hash":"9049db1d5d2ce83ad7e06618e31b9276e92654b766f5eefecde4473a09620365"},{"ts":"2026-06-29T11:01:12.671Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"tb-500","response":"I added explicit gaps in knowledge and named who claims what from anecdotes as instructed, as I am not Grok and my role is to contribute to the ledger with tier-honest claims.","tokens_in":2667,"tokens_out":398,"cost":0,"prev":"9049db1d5d2ce83ad7e06618e31b9276e92654b766f5eefecde4473a09620365","hash":"dbac4217fa308fc04aab9d554348c6fa949dbcc2065b4f5df6c51362e951a9e6"},{"ts":"2026-06-29T11:04:30.643Z","model":"gemini/gemini-2.5-flash","action":"collaborate","prompt":"","input":"tb-500","response":"As Gemini, I've added three tier-honest claims to address explicit gaps in knowledge (what_is_unknown) and clarify the status of ongoing research, using only provided source IDs. I also challenged an unsourced, overstrong claim regarding age-related decline.","tokens_in":2339,"tokens_out":539,"cost":0,"prev":"dbac4217fa308fc04aab9d554348c6fa949dbcc2065b4f5df6c51362e951a9e6","hash":"c00871cae55904bd8a150f84af2455684ad11e5dbdecd9d5d210700fe06b0c43"},{"ts":"2026-06-29T12:29:42.985Z","model":"repair","action":"repair","prompt":"","input":"tb-500","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_is_known, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_is_known, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c00871cae55904bd8a150f84af2455684ad11e5dbdecd9d5d210700fe06b0c43","hash":"1dc94cdd9b628836bed712534ac627eb94e9344924252a3723b53238e0311389"},{"ts":"2026-06-29T12:46:39.763Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_is_known, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_is_known, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1dc94cdd9b628836bed712534ac627eb94e9344924252a3723b53238e0311389","hash":"79222c11273c71018f7576eb41a755011458be9168b8ee36f1b8286182369f2f"},{"ts":"2026-06-29T12:46:40.562Z","model":"system/audit-repair","action":"claim","prompt":"","input":"tb-500 c37","response":"Per this ledger on TB-500: Thymosin Beta-4: 18 scientific and 10 anecdotal sources are catalogued; 21 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"79222c11273c71018f7576eb41a755011458be9168b8ee36f1b8286182369f2f","hash":"eb5af796ef844276016746f45e2e7d7a0ac4ab9f0092795053831ef72bcc80c5"},{"ts":"2026-06-29T12:46:40.614Z","model":"system/audit-repair","action":"claim","prompt":"","input":"tb-500 c38","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"eb5af796ef844276016746f45e2e7d7a0ac4ab9f0092795053831ef72bcc80c5","hash":"1e3da66baad9ecce3d966645eb03dfd6a7f0ed2e3b97defbb1de9478b2bd439e"},{"ts":"2026-06-29T12:46:40.782Z","model":"system/audit-repair","action":"claim","prompt":"","input":"tb-500 c39","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1e3da66baad9ecce3d966645eb03dfd6a7f0ed2e3b97defbb1de9478b2bd439e","hash":"fe4e8bddca332f74fa1ac64995d19613d292bf03377984520ef123074217d215"},{"ts":"2026-06-29T12:46:41.652Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fe4e8bddca332f74fa1ac64995d19613d292bf03377984520ef123074217d215","hash":"48d628e1ef00c21712b731d851a95fb85ccfd54da9578d206f383f54953d2014"},{"ts":"2026-06-29T13:25:13.104Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"48d628e1ef00c21712b731d851a95fb85ccfd54da9578d206f383f54953d2014","hash":"eeeaa8b13cc317de8e824fd7dc57aa6ed5c10b55615fe41fa2b6a898a9565c3c"},{"ts":"2026-06-29T13:25:14.278Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"eeeaa8b13cc317de8e824fd7dc57aa6ed5c10b55615fe41fa2b6a898a9565c3c","hash":"947ee5f53a3f8d7012cb95bdf8ee9400dfa2ac1115ca5deb76a5e1f8c94384d7"},{"ts":"2026-06-29T13:50:24.997Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"947ee5f53a3f8d7012cb95bdf8ee9400dfa2ac1115ca5deb76a5e1f8c94384d7","hash":"98890591df40d86f6b9cc84670020867919d678128b2271f9d4d07aa190845bc"},{"ts":"2026-06-29T13:53:42.835Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"98890591df40d86f6b9cc84670020867919d678128b2271f9d4d07aa190845bc","hash":"a1dddf057660c25d5075fe12221159050732e0244f45cfd005663035c7d03cd1"},{"ts":"2026-06-29T13:53:44.024Z","model":"system/audit-repair","action":"repair","prompt":"","input":"tb-500","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a1dddf057660c25d5075fe12221159050732e0244f45cfd005663035c7d03cd1","hash":"900a8bfca0327f6c98d58ce469964e61307b0fd849657e32447343e85de710bb"},{"ts":"2026-06-29T13:59:26.205Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"900a8bfca0327f6c98d58ce469964e61307b0fd849657e32447343e85de710bb","hash":"100f12fbb6373f557d1678ba9ff300f9173d0cc9183bdc2ea60d2a207a2021e8"},{"ts":"2026-06-29T13:59:34.019Z","model":"repair","action":"repair","prompt":"","input":"tb-500","response":"{\"materialized\":0,\"before\":[\"4 orphan sources (no claim link)\"],\"after\":[\"4 orphan sources (no claim link)\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"100f12fbb6373f557d1678ba9ff300f9173d0cc9183bdc2ea60d2a207a2021e8","hash":"0e5e16c749c83030c7993e2bc49419f0b9f7400ae9b0f33416fba557855ab8ca"},{"ts":"2026-06-29T14:19:53.667Z","model":"grok/grok-4.3","action":"synthesize_body","prompt":"","input":"tb-500","response":"## Regeneration vs degeneration — where this fits\nThe body breaks down tissue and rebuilds it at the same time. When breakdown stays ahead of repair, injury or disease persists. Most drugs block signals such as pain or swelling without rebuilding the tissue that created the signal. TB-500 is studied for repair pathways: it affects actin inside cells so repair cells can move to a site of damage and begin rebuilding structure. This places TB-500 in the regeneration column of the ledger.\n\n## What it is\nTB-500 is a fragment of thymosin beta-4, a 43-amino-acid peptide found in most mammalian cells. It is studied because it binds G-actin and influences cell movement, blood-vessel growth, and inflammation control. The ledger records 35 sources total on this compound.\n\n## How it works\nStep 1: TB-500 binds free G-actin inside cells.  \nStep 2: This binding frees up actin monomers for new filament assembly at the leading edge of a cell.  \nStep 3: Cells can therefore migrate toward injury sites.  \nStep 4: Migrating cells release signals that support new vessel formation and reduce excess inflammation.  \nStep 5: The net result is faster re-closure of wounds and faster deposition of repair matrix in animal models.\n\n## Why it would work (logic chain)\nIf actin sequestration lets cells move, then more repair cells reach the wound. If more cells reach the wound, then re-epithelialization and matrix deposition increase. If matrix deposition increases, then structural repair occurs sooner than in controls. Each link follows from the prior step.\n\n## Why people take it\nPeople take it when they want support for tissue that is slow to repair: tendons, ligaments, muscle tears, skin ulcers, or post-surgical sites. The goal is to shift the balance toward regeneration rather than prolonged degeneration.\n\n## How many people take it\nThe ledger does not contain population counts. No reliable figure exists for total users.\n\n## Evidence inventory\n- 1 human safety study (source s3)  \n- 2 human wound","tokens_in":7832,"tokens_out":1234,"cost":0,"prev":"0e5e16c749c83030c7993e2bc49419f0b9f7400ae9b0f33416fba557855ab8ca","hash":"7187bf242bc4b73a091cf6b8c8641de1bf15d48ea0700348f0042c6786d2b09e"},{"ts":"2026-06-29T15:07:20.227Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7187bf242bc4b73a091cf6b8c8641de1bf15d48ea0700348f0042c6786d2b09e","hash":"fe9b5170d7f0512ffb22f2d97dc3721675fd7502d52ff349988aa9b0ff67a782"},{"ts":"2026-06-29T15:07:53.493Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fe9b5170d7f0512ffb22f2d97dc3721675fd7502d52ff349988aa9b0ff67a782","hash":"1ed6309748c82aaae4eba2345201b4cce5297eaa8dd0850b0551960e469ec640"},{"ts":"2026-06-29T15:08:13.694Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1ed6309748c82aaae4eba2345201b4cce5297eaa8dd0850b0551960e469ec640","hash":"f7e97a1431fae412596dd2d23a79fc23f6782e766ebf0340597b15ee274a78c1"},{"ts":"2026-06-29T15:17:34.246Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f7e97a1431fae412596dd2d23a79fc23f6782e766ebf0340597b15ee274a78c1","hash":"6681ffc33e662e6ba4eab0c5c81f1f498bc395dbf04b107a435b86cbffbcf186"},{"ts":"2026-06-29T17:00:33.666Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6681ffc33e662e6ba4eab0c5c81f1f498bc395dbf04b107a435b86cbffbcf186","hash":"af3c751fdb28a757aa6c243526eda33f2add8387fb7b9e74969ad5f68b08353f"},{"ts":"2026-06-29T17:01:21.680Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"af3c751fdb28a757aa6c243526eda33f2add8387fb7b9e74969ad5f68b08353f","hash":"1b6c3e2226c30b40bc0a41ed5026fda9b9c4e8bc94a14e1c6d7ca4ed59357c47"},{"ts":"2026-06-29T17:02:33.027Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1b6c3e2226c30b40bc0a41ed5026fda9b9c4e8bc94a14e1c6d7ca4ed59357c47","hash":"9f28bbcac9bb2c4ae3713edd6f852be05b6d26c3614dc1a2e62c0759d699c9a2"},{"ts":"2026-06-29T17:03:09.274Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9f28bbcac9bb2c4ae3713edd6f852be05b6d26c3614dc1a2e62c0759d699c9a2","hash":"8f709bd0f522d8b53b9fe02f7a45a6f70d6ddea6fcc835ad65dd784155e719e6"},{"ts":"2026-06-29T17:03:52.670Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8f709bd0f522d8b53b9fe02f7a45a6f70d6ddea6fcc835ad65dd784155e719e6","hash":"6ff4c043ed8d5068aaea17ecff1de059cfe16c534b3d504f48f5f590cce3feba"},{"ts":"2026-06-29T17:04:29.303Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6ff4c043ed8d5068aaea17ecff1de059cfe16c534b3d504f48f5f590cce3feba","hash":"1d1e1c86714b0532f26141b4274988cbba4b40a0b5c0c469db8d3967c945d47d"},{"ts":"2026-06-29T17:04:48.764Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1d1e1c86714b0532f26141b4274988cbba4b40a0b5c0c469db8d3967c945d47d","hash":"00960bfd6b5810600f5ed4432d8826859142f9283af2e6bdad4127e4a18029f5"},{"ts":"2026-06-29T17:05:37.418Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"00960bfd6b5810600f5ed4432d8826859142f9283af2e6bdad4127e4a18029f5","hash":"30644a8e04381aa1654e05392aac2d802d931f3c6a09f4540eb9d4d496ae9317"},{"ts":"2026-06-29T17:06:40.016Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"30644a8e04381aa1654e05392aac2d802d931f3c6a09f4540eb9d4d496ae9317","hash":"64beb09f567ac47a8a394ce53c2bf79f1ee44f779ffde7261ff78ac17217ac01"},{"ts":"2026-06-29T17:07:11.659Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"64beb09f567ac47a8a394ce53c2bf79f1ee44f779ffde7261ff78ac17217ac01","hash":"c300913d4425affaa648dbaab1301507cdb964525d9e77bf3dfe8e278601f481"},{"ts":"2026-06-29T17:22:23.652Z","model":"grok-4.3","action":"sources","prompt":"","input":"tb-500","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c300913d4425affaa648dbaab1301507cdb964525d9e77bf3dfe8e278601f481","hash":"b7eab40aad5fd59ae39d9cce1ab76d9e07486115b7f1dac96635363d8301331e"},{"ts":"2026-06-29T19:06:02.143Z","model":"repair","action":"repair","prompt":"","input":"tb-500","response":"{\"materialized\":0,\"before\":[\"1 claims mislabeled preclinical (human language)\"],\"after\":[\"1 claims mislabeled preclinical (human language)\"],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":4}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b7eab40aad5fd59ae39d9cce1ab76d9e07486115b7f1dac96635363d8301331e","hash":"cae1d4774e0032c713d63afc91c890eb60453633ba88f308205b02d99e21168f"},{"ts":"2026-06-29T19:16:02.623Z","model":"repair","action":"repair","prompt":"","input":"tb-500","response":"{\"materialized\":0,\"before\":[\"1 claims mislabeled preclinical (human language)\"],\"after\":[\"1 claims mislabeled preclinical (human language)\"],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":4}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"cae1d4774e0032c713d63afc91c890eb60453633ba88f308205b02d99e21168f","hash":"d5c0190259ab3a1e7d50d82f9617a88af8f27f51f576a96d502beb9f181156bd"},{"ts":"2026-07-01T11:29:18.678Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented TB-500 (Tβ4 fragment) mechanism in the ledger: Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration (c1, tier human, source s1). Stepwise: binds free G-actin inside cells → frees actin monomers for new filament assembly at the leading edge → cells migrate toward injury sites → migrating cells release signals supporting new vessel formation and reduced excess inflammation → net result faster wound re-closure and repair matrix deposition in animal models. All other mechanistic claims (vascular repair via CCN5 (c44, s33), axon regeneration (c45, s34), kidney fibrosis/inflammation (c15, s14)) remain at mechanistic or preclinical tier.","tokens_in":7249,"tokens_out":225,"cost":0,"prev":"d5c0190259ab3a1e7d50d82f9617a88af8f27f51f576a96d502beb9f181156bd","hash":"211c3bb17b2fdc943f69e09bbe83fe4d52aab7c3683390b6ade2c6804d1a4300"},{"ts":"2026-07-01T23:11:39.055Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism in the ledger: TB-500 (Tβ4 fragment) binds free G-actin inside cells, freeing actin monomers for new filament assembly at the leading edge; this enables cell migration toward injury sites, supports new vessel formation (angiogenesis), and modulates inflammation. Net result described is faster wound re-closure and repair matrix deposition in animal models. Core claim (c1) cites source s1. No interaction_risk or limitations-slot claims present. Preclinical support (c2) from rat wound models (source s2). Human data limited to safety (c3, source s3) and specific wound types (c4, source s4); orthopaedic and other uses remain without established human evidence (quote-gated claims c6, c27, c41 etc. treated as low-confidence). Anecdotes (tier:anecdotal, e.g. c56, c57) separated and lower weight.","tokens_in":7249,"tokens_out":268,"cost":0,"prev":"211c3bb17b2fdc943f69e09bbe83fe4d52aab7c3683390b6ade2c6804d1a4300","hash":"d12c54dfbdd96317fb784f3fbd15973b1d55da6459ffdf21281de3760c2d8e93"},{"ts":"2026-07-01T23:55:01.451Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism in the ledger: TB-500 (fragment of thymosin beta-4) binds free G-actin inside cells; this frees actin monomers for new filament assembly at the leading edge of a cell; cells can therefore migrate toward injury sites; migrating cells release signals that support new vessel formation and reduce excess inflammation; the net result is faster re-closure of wounds and faster deposition of repair matrix in animal models (c1, s1).","tokens_in":7249,"tokens_out":155,"cost":0,"prev":"d12c54dfbdd96317fb784f3fbd15973b1d55da6459ffdf21281de3760c2d8e93","hash":"60ed80b7064c8bb87140e45798321b5c2d4e8171d33f617df19a2caa0365eefa"},{"ts":"2026-07-03T00:02:09.471Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented TB-500 mechanism in the ledger: binds free G-actin inside cells, freeing actin monomers for new filament assembly at the leading edge, enabling cell migration toward injury sites; migrating cells then release signals supporting new vessel formation and reduced excess inflammation, resulting in faster wound re-closure and repair matrix deposition in animal models (c1, c2). Human evidence is limited to one Phase 1 safety study (well tolerated, no dose-limiting toxicity) and two Phase 2 wound-healing trials (topical use accelerated healing in some stasis/pressure ulcer patients); most data are preclinical or anecdotal (c3, c4). No interaction_risk or limitations-slot claims exist for mechanism.","tokens_in":7249,"tokens_out":220,"cost":0,"prev":"60ed80b7064c8bb87140e45798321b5c2d4e8171d33f617df19a2caa0365eefa","hash":"302ec95da5ba2994759b93e4fbb3609dcf1f25ce1ca19ec9480213c841412758"},{"ts":"2026-07-03T00:04:27.979Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"The ledger documents TB-500 (Tβ4 fragment) mechanism as: binds free G-actin, frees monomers for new filament assembly at the cell leading edge, enabling migration of repair cells toward injury; migrating cells then support angiogenesis and modulate inflammation, resulting in faster wound re-closure and repair-matrix deposition in animal models (c1; s1). Preclinical support includes rat full-thickness wound models showing accelerated re-epithelialization (c2; s2). Human data are limited to Phase 1 safety (well tolerated, no dose-limiting toxicity; c3; s3) and one Phase 2 signal in specific ulcers (c4; s4). No new evidence is present; marketing volume is noted separately (c7).","tokens_in":7249,"tokens_out":233,"cost":0,"prev":"302ec95da5ba2994759b93e4fbb3609dcf1f25ce1ca19ec9480213c841412758","hash":"12c56c3885df621b2e012c476685438bd9439cafac4776b0df59fba5c165e8af"},{"ts":"2026-07-03T04:45:47.124Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism (no new evidence): TB-500 (fragment of thymosin beta-4) binds free G-actin inside cells, freeing actin monomers for new filament assembly at the leading edge. This enables cell migration toward injury sites; migrating cells then release signals supporting new vessel formation and reduced excess inflammation. Net result observed in animal models is faster wound re-closure and repair-matrix deposition. Core claim rests on actin sequestration promoting cell migration, angiogenesis, and inflammation modulation (c1, tier human, source s1). Preclinical rat wound model showed accelerated re-epithelialization (c2, tier preclinical, source s2). Human safety data exist (Phase 1 intravenous tolerability, c3, tier human, source s3) but no new mechanistic human data are recorded. Several quote-gated claims (c6, c13, c16, c27, c40–42, c46, c10, c9, c24, c33, c45) and anecdotal reports (multiple c56–c102) are present but do not alter the documented mechanism.","tokens_in":7249,"tokens_out":322,"cost":0,"prev":"12c56c3885df621b2e012c476685438bd9439cafac4776b0df59fba5c165e8af","hash":"76f4dba9f25d824579bc576cd0b917b3371249ec59764706614c429b5c8ccd64"},{"ts":"2026-07-03T05:05:29.044Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism for TB-500 in the ledger: TB-500 (synthetic fragment of thymosin beta-4) binds free G-actin inside cells, freeing actin monomers for new filament assembly at the leading edge of cells. This enables cell migration toward injury sites. Migrating cells release signals that support new vessel formation and reduce excess inflammation. Net result: faster wound re-closure and repair matrix deposition in animal models. Core claim (c1, source s1): “Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration.” Preclinical support (c2, source s2): topical or systemic Tβ4 accelerates wound healing and re-epithelialization in rat full-thickness wound models. No interaction_risk or limitations-slot claims present. All other listed claims are efficacy, marketing, or anecdotal and not required for mechanism.","tokens_in":7249,"tokens_out":243,"cost":0,"prev":"76f4dba9f25d824579bc576cd0b917b3371249ec59764706614c429b5c8ccd64","hash":"5aef827ae6cffd84d45ab92572a6a3aaa14a1d58426e6a47260bc20282f4a940"},{"ts":"2026-07-03T05:11:50.916Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism in the ledger: TB-500 (Tβ4 fragment) binds free G-actin (c1, source s1), freeing actin monomers for new filament assembly at the leading edge of cells (c1). This enables cell migration toward injury sites (c1), followed by release of signals supporting new vessel formation (angiogenesis) and reduced excess inflammation (c1). Net result in models is faster wound re-closure and repair-matrix deposition (c2, source s2). No new evidence added; all claims drawn from existing ledger entries. Human data remain sparse (s3, s4); most sources are preclinical or anecdotal.","tokens_in":7249,"tokens_out":200,"cost":0,"prev":"5aef827ae6cffd84d45ab92572a6a3aaa14a1d58426e6a47260bc20282f4a940","hash":"97ea43b1fc28e004d94bde76beb085314e3e9ed085029ee44961133aeebabd51"},{"ts":"2026-07-03T17:43:10.228Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism for TB-500 (Tβ4 fragment) in the ledger: binds free G-actin inside cells, freeing actin monomers for new filament assembly at the leading edge. This enables cell migration toward injury sites. Migrating cells release signals supporting new vessel formation and reduced excess inflammation. Net result in models: faster wound re-closure and repair-matrix deposition. Core claim c1 (tier human, source s1) states: 'Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration.'","tokens_in":7249,"tokens_out":169,"cost":0,"prev":"97ea43b1fc28e004d94bde76beb085314e3e9ed085029ee44961133aeebabd51","hash":"d49cd490a07748dbc3563579160b0eaa0d25dadc23cf1d9b2ee822cb58afedd3"},{"ts":"2026-07-04T22:09:15.362Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented TB-500 mechanism in the ledger: Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration (c1, tier human, source s1). Stepwise description: binds free G-actin, frees monomers for new filament assembly at the leading edge, enables cell migration to injury sites, supports new vessel formation, reduces excess inflammation, and results in faster wound re-closure and repair matrix deposition in animal models. No new evidence added; all from existing ledger.","tokens_in":7249,"tokens_out":162,"cost":0,"prev":"d49cd490a07748dbc3563579160b0eaa0d25dadc23cf1d9b2ee822cb58afedd3","hash":"6c63b55ed9fa1861f1c8fef4b532a190223ff85774caabc2baeeba116bab42e7"},{"ts":"2026-07-06T02:31:41.538Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism per ledger: TB-500 (Tβ4 fragment) binds free G-actin, freeing monomers for new filament assembly at the cell's leading edge, enabling cell migration toward injury sites; migrating cells then release signals supporting new vessel formation and reduced excess inflammation, resulting in faster wound re-closure and repair matrix deposition in animal models (c1, s1; c2, s2). No new evidence added; ledger lists 35 sources total (1 human safety, 2 human wound-healing, 28 preclinical/mechanistic, 10 anecdotal).","tokens_in":7249,"tokens_out":197,"cost":0,"prev":"6c63b55ed9fa1861f1c8fef4b532a190223ff85774caabc2baeeba116bab42e7","hash":"26bfb8de598039fb3b0f7c00c547d70ef469e9fa243dbb156a6bc4086d943108"},{"ts":"2026-07-06T03:08:06.235Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism in the ledger: TB-500 (Tβ4 fragment) binds free G-actin inside cells, freeing actin monomers for new filament assembly at the leading edge, enabling cell migration toward injury sites; migrating cells then release signals supporting new vessel formation and reduced excess inflammation, resulting in faster wound re-closure and repair-matrix deposition (primarily in animal models). Core claim c1 (tier human, weight 0.8, source s1) states Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration. Step-by-step logic chain and regeneration framing are given in the body_excerpt. No new evidence; all mechanism claims drawn from existing ledger sources only.","tokens_in":7249,"tokens_out":202,"cost":0,"prev":"26bfb8de598039fb3b0f7c00c547d70ef469e9fa243dbb156a6bc4086d943108","hash":"c497281ddd49ff468009084b78de26cc9171dd638c85f7c75fec18d499ba5937"},{"ts":"2026-07-07T03:41:55.298Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism from the TB-500 ledger: TB-500 (fragment of thymosin beta-4) binds free G-actin inside cells, freeing actin monomers for new filament assembly at the leading edge of a cell. This enables cell migration toward injury sites. Migrating cells release signals that support new vessel formation and reduce excess inflammation. The net result is faster wound re-closure and faster deposition of repair matrix in animal models (c1, s1; c2, s2).","tokens_in":7249,"tokens_out":169,"cost":0,"prev":"c497281ddd49ff468009084b78de26cc9171dd638c85f7c75fec18d499ba5937","hash":"a880b8d7ba970c9e6b6df0e6b1fda3c806b74d19d0fe971bc08b2e0cd5cc37d6"},{"ts":"2026-07-07T03:43:31.426Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented TB-500 mechanism in the ledger centers on actin sequestration: TB-500 binds free G-actin, freeing monomers for new filament assembly at the leading edge of cells, enabling migration toward injury sites, release of signals supporting vessel formation and reduced excess inflammation, resulting in faster wound re-closure and repair matrix deposition in animal models (c1, c2). Human data are limited to a Phase 1 safety study showing good tolerability with no dose-limiting toxicity (c3) and a Phase 2 topical trial showing accelerated healing in some stasis/pressure ulcer patients (c4). Preclinical sources confirm wound healing acceleration in rat models (c2). All other claims are anecdotal or quote-gated with low effective weight; no interaction_risk or limitations-slot claims are present in the topology. The ledger records 35 sources total, predominantly preclinical or anecdotal.","tokens_in":7249,"tokens_out":272,"cost":0,"prev":"a880b8d7ba970c9e6b6df0e6b1fda3c806b74d19d0fe971bc08b2e0cd5cc37d6","hash":"6d58773ec9ab99c22c6ec93595e5f71ba147a376d059740b09667a48633c8423"},{"ts":"2026-07-07T03:44:15.774Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism in the ledger: TB-500 (synthetic fragment of thymosin beta-4) binds free G-actin inside cells, freeing actin monomers for new filament assembly at the cell's leading edge. This enables cell migration toward injury sites; migrating cells then release signals supporting new vessel formation and reduced excess inflammation. Net result observed in animal models is faster wound re-closure and repair-matrix deposition. Core mechanism claim (c1) is supported by review source s1. Preclinical support for accelerated re-epithelialization in rat wound models (c2) from source s2. No new evidence beyond ledger contents.","tokens_in":7249,"tokens_out":197,"cost":0,"prev":"6d58773ec9ab99c22c6ec93595e5f71ba147a376d059740b09667a48633c8423","hash":"b566c37c28b7c0686fb4cafab33206ea8b4a60cda8e1881132e2f9fd0d3cf4a6"},{"ts":"2026-07-07T03:46:26.419Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism in the ledger: TB-500 (synthetic fragment of thymosin beta-4) binds free G-actin, freeing monomers for new filament assembly at the cell leading edge, enabling repair-cell migration to injury sites; migrating cells then release signals supporting vessel formation and reduced excess inflammation, yielding faster wound re-closure and repair-matrix deposition in animal models (c1 from s1; steps 1–5 in body excerpt). Core claim is actin sequestration promoting cell migration, angiogenesis, and inflammation modulation (c1). Preclinical support includes rat full-thickness wound models showing accelerated re-epithelialization (c2 from s2). Human data are limited to one Phase 1 safety study (well tolerated, no dose-limiting toxicity, c3 from s3) and two wound-healing trials (c4 from s4; c16 from s15, quote-gated). No new evidence added; interaction_risk and limitations slots contain no safety signals for this query.","tokens_in":7249,"tokens_out":298,"cost":0,"prev":"b566c37c28b7c0686fb4cafab33206ea8b4a60cda8e1881132e2f9fd0d3cf4a6","hash":"47abed2af8e2ef2ba97d123d359f37a047fd8badf8097a3b718219b1502648c6"},{"ts":"2026-07-07T03:48:51.561Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism per ledger: TB-500 (Tβ4 fragment) binds free G-actin, freeing monomers for new filament assembly at the leading edge, enabling cell migration toward injury. Migrating cells then release signals supporting angiogenesis and reduced excess inflammation, yielding faster wound re-closure and repair-matrix deposition in animal models (c1 tier human from s1; c2 tier preclinical from s2). No new evidence added; all claims drawn from existing ledger entries.","tokens_in":7249,"tokens_out":163,"cost":0,"prev":"47abed2af8e2ef2ba97d123d359f37a047fd8badf8097a3b718219b1502648c6","hash":"7808a4c6229e058e158a990bd373f7183e9e5c881e09b4de97668fff0088ed60"},{"ts":"2026-07-07T03:50:54.727Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented TB-500 mechanism in the ledger centers on actin sequestration: TB-500 binds free G-actin (c1), freeing monomers for new filament assembly at the cell leading edge, enabling cell migration to injury sites, release of signals supporting angiogenesis, and modulation of inflammation. Net effect reported as faster wound re-closure and repair-matrix deposition in animal models. Source s1 (review) states thymosin beta-4 “plays a vital role in the repair and regeneration of injured cells and tissues.” Preclinical support includes rat full-thickness wound models (c2, source s2). Human data are limited to safety (c3, source s3) and specific wound-healing signals (c4, source s4); no new evidence added.","tokens_in":7249,"tokens_out":253,"cost":0,"prev":"7808a4c6229e058e158a990bd373f7183e9e5c881e09b4de97668fff0088ed60","hash":"3771fced9dc2ebdfb51d95e7842c08ed2a1f0665e89483f624a8a89ea875e930"},{"ts":"2026-07-07T04:07:29.867Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism in the ledger: TB-500 (synthetic fragment of thymosin beta-4) binds free G-actin inside cells. This frees actin monomers for new filament assembly at the leading edge of a cell, allowing repair cells to migrate toward injury sites. Migrating cells then release signals that support new vessel formation and reduce excess inflammation, resulting in faster wound re-closure and repair matrix deposition in animal models. Core claim (c1, source s1) states Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration. Preclinical support (c2, source s2) shows accelerated re-epithelialization in rat wound models. Human data on mechanism itself are absent; safety (c3, source s3) and limited wound-healing signals (c4, source s4) exist but do not address mechanism in humans.","tokens_in":7249,"tokens_out":273,"cost":0,"prev":"3771fced9dc2ebdfb51d95e7842c08ed2a1f0665e89483f624a8a89ea875e930","hash":"e7abd0ef1b6bfdde3ee99e2ff385e4041b3c61b07e3869eaada4468adebf19d6"},{"ts":"2026-07-07T04:09:37.821Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism from ledger: TB-500 (Tβ4 fragment) binds free G-actin, frees monomers for new filament assembly at the leading edge, enabling cell migration toward injury; migrating cells then release signals supporting new vessel formation and reducing excess inflammation, producing faster wound re-closure and repair-matrix deposition in animal models (c1, c2). No new evidence supplied; all claims drawn from existing topology only.","tokens_in":7249,"tokens_out":154,"cost":0,"prev":"e7abd0ef1b6bfdde3ee99e2ff385e4041b3c61b07e3869eaada4468adebf19d6","hash":"9719fc186d02847b8e37b918fb272658a2fe7d1a365c58faf78a3202b933c9d9"},{"ts":"2026-07-07T04:40:44.976Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism of TB-500 (Tβ4 fragment) in the ledger: binds free G-actin, sequesters it, frees monomers for new filament assembly at the leading edge of cells, enabling cell migration to injury sites; migrating cells then release signals supporting angiogenesis and reduced excess inflammation, leading to faster wound re-closure and repair-matrix deposition in animal models. Core claim supported by review source s1 (c1) and mechanistic description in the body; no new evidence added. Safety-first: no interaction_risk or limitations-slot claims present for mechanism. All human data remain sparse; most evidence preclinical or anecdotal.","tokens_in":7249,"tokens_out":188,"cost":0,"prev":"9719fc186d02847b8e37b918fb272658a2fe7d1a365c58faf78a3202b933c9d9","hash":"bb95d6973c5735237933074189589c4c8e6c9a9c2e1ef3cae5e74e766920cc92"},{"ts":"2026-07-07T05:18:10.092Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented mechanism from the ledger: TB-500 (Tβ4 fragment) binds free G-actin inside cells, freeing actin monomers for new filament assembly at the leading edge; this enables cell migration toward injury sites, release of signals supporting new vessel formation, and modulation of inflammation, leading to faster wound re-closure and repair matrix deposition in animal models. Core claims: c1 (actin sequestration, cell migration, angiogenesis, inflammation modulation; tier human, source s1), c3 (Phase 1 IV safety/tolerability in healthy volunteers; tier human, source s3), c4 (Phase 2 topical acceleration in some stasis/pressure ulcer patients; tier human, source s4), c2 (rat wound re-epithelialization increase; tier preclinical, source s2). No new evidence; human data sparse, most evidence preclinical or anecdotal. Quote-gated claims (e.g., c6, c13, c16, c27, c40, c41, c42, c46) treated as low-confidence. No interaction_risk/limitations claims present in the provided topology.","tokens_in":7249,"tokens_out":335,"cost":0,"prev":"bb95d6973c5735237933074189589c4c8e6c9a9c2e1ef3cae5e74e766920cc92","hash":"562b241572f73a306e300bebff8512dc719fb8111a4a8607a7ee33e6af8a0937"},{"ts":"2026-07-11T14:38:52.094Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","response":"Documented TB-500 mechanism in the ledger (no new evidence): TB-500 (fragment of thymosin beta-4) binds free G-actin inside cells, freeing actin monomers for new filament assembly at the leading edge; this enables cell migration toward injury sites, release of signals supporting new vessel formation, and reduction of excess inflammation, resulting in faster wound re-closure and repair matrix deposition in animal models. Core claim: Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration (c1, s1). Preclinical support includes rat full-thickness wound models showing accelerated re-epithelialization (c2, s2). Human data are limited to safety (c3, s3) and specific wound-healing trials (c4, s4); no new mechanistic evidence is present.","tokens_in":7310,"tokens_out":243,"cost":0,"prev":"562b241572f73a306e300bebff8512dc719fb8111a4a8607a7ee33e6af8a0937","hash":"629b2c9bee5e191e376d74a9220efe94a7459efeec30fc7d0330fdcdf6ecaa54"},{"ts":"2026-07-17T02:42:11.927Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500","response":"25 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"629b2c9bee5e191e376d74a9220efe94a7459efeec30fc7d0330fdcdf6ecaa54","hash":"5fec39af3770cd4c0e85af9a2bb2855b636fcfb0b17229556f0b029b21bea6e2"}]}